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Introduction
There is a significant clinical need for improving the detection of prostate cancer metastases and measuring the response of tumors to systemic therapy. The most common method of screening for prostate cancer, a prostate specific antigen (PSA) blood test, is notoriously non-specific and is commonly elevated in benign prostate hyperplasia (BPH), prostatitis, and low-risk indolent prostate cancer. Prostate cancer survival is high for the 91% of patients that are diagnosed with local or regional disease and PSA testing is associated with over-diagnosis and treatment of indolent disease (1) . On the other hand, prostate cancer is the second most common cause of cancer related deaths in men and one of the great challenges in treating it is distinguishing the patients who do not need to be treated from those for whom it is life threatening (2) . Metastases, and especially bone metastases, represent the primary cause of morbidity and mortality and prostate cancer survival rates fall quickly once the disease has metastasized to distant sites (2) .
Detection of metastases, therefore, stratifies a subset of patients that need to be treated aggressively and systemically from the large majority of patients where more conservative local therapies or active surveillance is preferred. Following the detection of distant metastases, androgen deprivation becomes the standard of care and PSA tests are frequently used to monitor the effectiveness of androgen deprivation and the development of castration resistant prostate cancer (CRPC). However, PSA levels can only measure the response of the tumors as a whole and cannot determine whether there is an androgen independent subset of tumors that fails to respond and may necessitate the use of targeted radiation or chemotherapy. There is a need for an imaging modality that can improve the early detection and localization of prostate cancer metastases and image response to androgen deprivation therapy in order to guide therapeutic decision-making.
Despite the large influence of bone metastases on patient prognosis and therapy decisions, the current methods of detecting them are unsatisfactory. Most Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on October 17, 2014; DOI: 10.1158/1078-0432.CCR- bone formation in response to osteoblastic prostate cancer bone metastases, though other methods are at various stages of development (3, 4) .
Bone scans are clinically recommended for symptomatic patients and asymptomatic men with serum PSA >10-20ng/mL, however, due to relatively low sensitivity of bone scans and their inability to detect metastases to other sites the presence of prostate cancer recurrence and/or metastasis often must be inferred based on other risk factors such as a rising PSA in a patient who has received a radical prostatectomy (4) .
Recently 18 F-Fluoride PET bone scans have shown improved sensitivity over 99m Tc-MDP in initial small clinical trials and are currently the subject of a Phase III study to determine whether their use improves metastasis detection (5) (6) (7) (8) . However, while the sensitivity of bone metastasis detection may be improved using 18 F-Fluoride bone scans, bone scans are obviously limited to detecting metastases to bone without the ability to image local prostate cancer or metastases to other sites.
Bone scans also have considerable false positives due to any benign process that increases bone formation such as trauma and fractures, degenerative diseases (e.g. osteoporosis), Paget's disease, and inflammatory processes (e.g. arthritis) which are relatively common in the elderly patients most likely to develop prostate cancer (4, 8) . Bone scans, additionally, have difficulty measuring response to therapy due to the flare phenomenon where uptake in bone scan lesions often increases in response to therapy due to bone healing in response to the shrinking tumor. This flare can last for months after successful therapy has been initiated and lesions may continue to appear on bone scans long after the viable tumor has been eliminated (4).
While the mainstay of metastatic prostate cancer therapy is androgen deprivation therapy (ADT), patients progress to CRPC a median of 2-3 years after initiating treatment (9) . MDV-3100
(enzalutamide) is a second-generation anti-androgen that has recently won FDA approval for the treatment of CRPC (10) . MDV-3100 has continued efficacy in cell lines resistant to other anti-androgens and results in a larger repression of androgen dependent genes and shorter time period to maximal efficacy than castration in mouse models (11) (12) (13) . A phase III study of MDV-3100 showed a ≥50% PSA decrease in 54% of patients who had previously failed both
Research. ADT and chemotherapy regimens and prolonged median survival 4.8 months over placebo (14) .
However, many patients do not respond to therapy with MDV-3100 and many initial responders develop resistance rapidly possibly through the generation of constitutively active splice variants that lack the AR C-terminal ligand binding domain on which MDV-3100 acts (15) (16) (17) . A method of imaging the activity of the androgen receptor signaling axis in vivo could lead to improved therapeutic strategies and could allow for targeted radiation therapy or a more prompt transition to alternative androgen deprivation agents or systemic chemotherapy in the patients whose tumors reactivate the androgen-signaling axis.
Prostate stem cell antigen (PSCA) is highly expressed in 83-100% of prostate cancers and overexpressed in the great majority of prostate cancer bone metastases (87-100%) and in many metastases to other sites (67% liver, 67-95% lymph node) (18-21). Its expression correlates with the Gleason score, tumor invasion, androgen independence, metastasis, and a poor prognosis (21) (22) (23) (24) (25) (26) . The PSCA promoter contains an androgen response element and PSCA expression is regulated by androgens in the normal mouse prostate (27, 28) . Likewise, androgen deprivation decreases PSCA mRNA expression in human high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer (29, 30) . We have previously shown that immunoPET with an affinity matured 124 I-labeled A11 anti-PSCA minibody, an antibody fragment with pharmacokinetics optimized for imaging, can be used for specific and quantitative imaging of PSCA expression in vivo (31) (32) (33) . We therefore hypothesize that imaging PSCA expression using the A11 minibody may outperform bone scans for imaging prostate cancer bone metastases and allow for imaging changes in PSCA expression in response to androgen deprivation. In this work, we will compare the sensitivity of the A11 minibody to 18 F-Fluoride bone scans for detecting bone tumors using a naturally PSCA expressing, purely osteoblastic, LAPC-9 intratibial xenograft model. We will also investigate changes in PSCA expression in LAPC-9 subcutaneous xenografts in response to androgen deprivation with MDV-3100 and demonstrate that anti-PSCA A11 minibody immunoPET can image these changes in vivo.
Research. 
Materials and Methods
Subcutaneous and intratibial xenograft models LAPC-9 subcutaneous (s.c.) xenografts were passaged surgically in male SCID mice as previously described (34) . Single cell suspensions of LAPC-9 cells were prepared by digesting freshly excised LAPC-9 s.c. xenografts in 0.1% Pronase (Sigma) in Iscove's Modified Dulbecco's Medium (IMDM, Gibco) for 18 minutes at room temperature (35, 36) . The cells were then passaged through 18 gauge needles and strained through a 70µm cell strainer (BD Biosciences).
1×10
5 viable cells were prepared in 10µL of 1:1 Media:Matrigel and injected into the tibias of anesthetized male SCID mice by drilling a needle through the proximal end of the tibial plateau.
Once the needle tip entered the intramedullary space of the tibial metaphysis, the cells were slowly injected and the needle was removed (37) . A sham injection, where the needle was inserted using the same method, but only Media:Matrigel was injected, was performed on the contralateral leg. Injections of PSCA-Negative 22rv1 cells and 22rv1×PSCA cells transfected with PSCA were used respectively as negative and positive controls (see supplemental materials).
All animal experiments were conducted in compliance with a protocol approved by the Institutional Animal Care and Use Committee of the University of California-Los Angeles. and microCT were automatically co-registered based on empirically determined scanner alignments. All image manipulation and quantification was performed using AMIDE (38) .
Alignment was manually verified and adjusted using the bladder as a fiduciary marker. Uptake (%ID/g) was then quantified from the co-registered microPET/CT images using microCT isocontour ROIs (≥200 Hounsfield units) to capture a region encompassing either only the tumor bearing tibia or the sham tibia. The mean value of the microPET scan was converted to %ID/g using the decay corrected injected dose of 18 F-Fluoride and an empirically determined cylinder factor for 18 F.
Either immediately following the 18 F-Fluoride bone scan or the day following the bone scan the intratibial tumor bearing mice were injected with ∼3µg
124 I-labeled A11 minibody.
Radiolabeling, purification, and immunoreactivity were performed as previously described except for the much higher specific activity used here (∼30-50µCi/µg) (32). 44 hours after A11 minibody injection, the mice again received microPET/CT scans. The mice were then either kept for serial imaging at later time points or at the last time point sacrificed for biodistribution as previously described (32) . The images were analyzed using the same method as for the 
High resolution ex vivo microCT and histology
Following biodistribution, tibias were stored in 10% phosphate buffered formalin until radioactivity had decayed. The tibias were then analyzed ex vivo by 20µm resolution microCT (µCT40, SANCO Medical). Volume renderings were generated with OsirX 5.6 (39). The tibia samples were then to single cell suspensions by incubation in 1mg/mL collagenase IV (Sigma) in HBSS for 1 hour at 37
• C. The cells were then passaged through 18 and 24 gauge needles followed by a 70µM cell strainer (BD Biosciences). 5×10 5 LAPC-9 cells from each tumor were incubated in 16µg/mL (∼100nM) 1G8 mouse anti-PSCA antibody (produced as previously described) followed by 8µg/mL (∼50nM) Dylight-649 conjugated anti-mouse-Fc γ secondary antibody (Jackson ImmunoResearch) (40 
Data analysis
Statistical analysis of both the bone scans and the immunoPET scans in the intratibial model were performed using two-way repeated measure ANOVA with intra-time-point significance testing and adjustments for multiple comparisons performed using the Holm-Šidák method. As the variance of the A11 immunoPET dataset increases significantly as the uptake increases, a log-transformation was applied to fulfill the homoscedasticity requirement of both ANOVA and Holm-Šidák before significance testing. Significance testing of the MDV-3100 response to therapy model was performed using two-tailed Student's t-tests. The 95% confidence level (p<0.05) was used for all analysis. Except where indicated otherwise all values are reported as mean±SD. All microPET images are displayed as full thickness maximum intensity projections.
Results

Radiolabeling
124 I-labeled A11 minibody used in the intratibial xenograft model had a mean specific activity of 23.7±6.5µCi/µg (n=8). After purification by size exclusion, the mean purity of the protein injected was 95±5% with immunoreactivity of 62±5%. For the MDV-3100 treatment model, the specific activity for the pre-treatment imaging was 1.23µCi/µg with injected radiochemical purity of 93.8%
and immunoreactivity of 72.7%. The post-treatment imaging had specific activity of 2.38µCi/µg, radiochemical purity of 98.6%, and immunoreactivity of 83.3%. Research. 
Comparison of
A11 minibody immunoPET imaging shows intratibial tumor targeting which can be appreciated above blood activity in 67% of mice (4/6) at 4 weeks, 100% of mice (6/6) at 6 weeks and 100% of mice at 8 weeks (2/2) post-xenograft implantation (Figure 2A) . Imaging of two mice at 8 weeks post-intratibial tumor implantation shows that the tumor has invaded through the bone and into the surrounding muscle. Quantification of the serial A11 immunoPET scans shows an overall increase in tibial uptake of the A11 minibody in the tumor bearing tibia across all time points (p<0.0001, two-way ANOVA), with an increase in the positive tibia over time (p=0.001). Due to the high specificity of the A11 minibody and universally low background in normal bone, the positive tibia has significantly higher uptake at all time points ( Figure 2B ). The high specificity of A11 minibody, therefore, allows for highly sensitive imaging of bone tumors as any bone uptake above blood can be interpreted as a PSCA expressing tumor.
Biodistribution of the LAPC-9 mice at 6 (n=4) or 8 weeks (n=2) post-tumor-implantation confirms the results of the immunoPET imaging ( Table 1 
A11 minibody immunoPET of mice bearing negative control 22rv1 intratibial tumors (n=5)
showed no distinguishable intratibial uptake by microPET and showed only a small increase in tibial uptake (0.36±0.19%ID/g) compared to the contralateral sham tibia (0.08±0.02%ID/g) by biodistribution (p=0.025). The small increase in intratibial uptake in the 22rv1 tumor was less than the blood activity (0.40±0.11%ID/g) and was likely a result of the enhanced permeability and retention (EPR) effect uptake due to malformed tumor vasculature. Biodistribution of a mouse bearing a 22rv1×PSCA intratibial xenograft at 6 weeks post-injection showed uptake of 3.31%ID/g for the 22rv1×PSCA tibia, 46.9 times higher than the sham tibia, 8.5 times higher than tibias bearing 22rv1 tumors, and 10.7 times higher than blood (Supplemental Table 1 and Supplemental Figures 1-4 
Ex vivo microCT and Histology
Gross analysis, ex vivo microCT, and histology confirm the presence of an osteoblastic intratibial tumor with spiculated bone formation in each mouse. High resolution ex vivo microCT imaging of the LAPC-9 xenograft bearing tibias and the sham controls shows spiculated bone formation in the LAPC-9 bearing tibias with sham injected tibias showing normal appearing bone ( Figure 3A) .
Histology of LAPC-9 bearing tibias shows osteoblastic tumor formation, consistent with previous reports, whereas histology of sham injected tibias shows normal bone marrow ( Figure 3B) (35, 36, (41) (42) (43) (44) (45) (46) . For mice that grew muscle tumors due to missed intratibial injections, neither gross analysis, nor histology, showed the presence of tumor cells in the intramedullary space and on biodistribution only the ipsilateral muscle uptake of A11 minibody was elevated due to the tumor presence and these mice were excluded from the analysis.
Changes in PSCA expression with MDV-3100 treatment
Quantitative flow cytometry on digested LAPC-9 tumors following 7 days of treatment with MDV-3100 (40mg/kg) or vehicle shows that MDV-3100 treatment downregulates PSCA expression 62.8±4.9% (p<0.0001, n=4) compared to the vehicle treated control ( Figure 4A ).
Quantitative flow finds expression of 4.75×10
5 PSCA antigens per cell for vehicle treated mice whereas mice treated with MDV-3100 express only 1.65×10 5 PSCA antigens per cell.
ImmunoPET imaging of PSCA downregulation in response to androgen deprivation therapy
Partial volume corrected quantification of the pre-treatment results shows equivalent tumor volumes and uptake in the two groups before treatment is initiated (2.43±0.428%ID/g Vehicle, 2.65±0.72%ID/g MDV-3100, p=0.46, Figure 4C ). After one week of treatment with MDV-3100
Research. tumor volumes show no significant difference as measured by CT (p=0.54) or by mass (p=0.53).
However, following treatment the A11 minibody uptake in the MDV-3100 treated cohort is 29% lower than in the control group by partial volume corrected microPET (3.70±0.20%ID/g Vehicle vs 2.61±0.23%ID/g MDV-3100, p<0.003, Figure 4B and Figure 4C ) and 24.0% lower than in the vehicle treated controls by biodistribution (p=0.03, Table 2 ).
Normalizing post-treatment imaging by the pre-treatment imaging similarly shows uptake in the MDV-3100 treated group 32% lower than the vehicle treated group (p=0.0003). However, rather than the MDV-3100 treated group decreasing from the baseline scan, we find that the MDV-3100 treated group is not significantly changed from pre-treatment (Pre:Post treatment ratio 1.10±0.16, p=0.90) and rather the difference post-treatment is due to an increase in the vehicle treated group between the scans (Pre:Post treatment ratio 1.61±0.26, p=0.0002).
Discussion
An ideal imaging modality for prostate cancer would allow for early detection of metastases that would inform treatment decisions. Imaging of prostate cancer metastases with an imaging agent specific to the tumor itself instead of imaging a downstream process such as bone formation could yield both higher sensitivity and specificity for detecting prostate cancer bone metastases as well as the potential to image local prostate cancer and metastases to other sites. An ideal imaging modality could likewise determine whether a chosen therapy is effective in a patient. While PSA blood tests can measure the response of the tumors in aggregate, they cannot detect whether only a subset of lesions are resistant to therapy. Molecular imaging of androgen receptor (AR) activity could yield more detailed information regarding individual tumor response to androgen deprivation therapy and development of resistance through the reactivation of AR pathways. ImmunoPET imaging with radiolabeled antibodies targeted to cell surface biomarkers has shown potential for use in this role (13, 31, 47 
the entire tibia was the least biased method of comparing both A11 immunoPET and bone scans and in vivo and ex vivo measurements using the A11 minibody, the tumor makes up only a fraction of the tibial volume and mass and the %ID/g is decreased by the inclusion of bone and other non-tumor tissue in the measurement.
The results of this work indicate that the A11 minibody has the potential to translate into an imaging agent with higher sensitivity and specificity than bone scans for imaging prostate cancer bone metastases in the clinic. In addition, while bone scans are limited to the detection of relatively large bone metastases that cause osteoblastic changes in the surrounding bone, immunoPET imaging can not only image tumors before changes are seen on bone scan, but also image tumors in locations other than bone. Lymph node metastases, lung metastases, liver metastases, and metastases to other locations have been shown to express PSCA and may be able to be imaged with A11 minibody immunoPET adding to its diagnostic value as up to 19% of patients have been found to have only visceral metastases with no bone involvement (18, 19, 48 ).
In addition, PSCA expression has been correlated with tumor stage, metastatic potential, and poor outcomes and imaging of PSCA may help stratify patients with high-risk local disease even in the absence of metastases (21) (22) (23) (24) (25) (26) .
It has previously been suggested that PSCA may be downregulated in prostate cancer in response to androgen deprivation (27) (28) (29) (30) . In this work, we found that treatment of mice bearing naturally PSCA expressing LAPC-9 xenografts with the anti-androgen MDV-3100 causes a significant, Modeling work by Thurber and Weissleder has suggested that antibody uptake into a tumor will only directly reflect antigen expression when the binding sites are relatively close to saturation and that, otherwise, the antibody uptake will be limited by the rate of antibody extravasation from the vasculature and diffusion into the tissue (49) . However, large antibody doses and receptor saturation produces a blocking effect that reduces imaging contrast and this effect needs to be balanced with the desire for antigen quantitation. While, the dose of A11 minibody in the response to therapy experiments was increased, the PSCA antigens remained relatively far from saturation and hence the decreased uptake of A11 minibody into the tumor (29%) does not directly reflect the degree of PSCA downregulation (63%). The decrease in A11 minibody uptake with MDV-3100 treatment is significant by both microPET/CT and biodistribution. However, the picture is complicated by comparison to the pre-treatment imaging. Rather than a simple decrease in A11 minibody uptake in the MDV-3100 treated mice compared to the pre-treatment imaging, we instead see an increase in the vehicle treated mice. A11 minibody uptake increased by 59.7±8.5% (p=0.0002) in the vehicle treated mice compared to the pre-treatment imaging while the MDV-3100 treated mice show no significant difference between pre-and post-treatment scans (p=0.90). These results cannot be explained by differences in Vehicle and MDV-3100 cohort tumor volumes, masses, or necrosis as no significant differences in these variables were observed (Supplemental Figures 5-6 ). The result was also not due to residual activity from the pre-treatment scan as residual activity was minimal and equivalent between the groups. Other explanations for the increase in uptake posttreatment includes changes in tumor vascularity and permeability as the tumors of both cohorts grew in the 7 days between scans. We recently published a method that uses diffusion-limited kinetic modeling of dynamic imaging with the A11 minibody tumor to measure permeability, vascularity, and antigen concentration independently which we intend to utilize to address these questions in future works (50) . Regardless of the cause of the baseline shift between pre-and post-therapy While the explanation for the increase in A11 minibody uptake in the vehicle treated group between the pre-and post-treatment scans requires further investigation, there was an unequivocal decrease in uptake in the MDV-3100 treated mice compared to the vehicle control that is likely due to the PSCA downregulation seen by ex vivo flow cytometry.
In summary, the majority of local prostate cancer tumors and metastases express PSCA and its expression correlates with tumor grade, stage, invasiveness, and metastatic potential. The A11 anti-PSCA minibody has shown the ability to specifically image PSCA expressing cells in vivo and has potential diagnostic utility in noninvasive imaging, staging, and risk stratification of prostate cancer (32) . In this work, the A11 minibody achieved higher sensitivity and specificity than Research. 
